Last updated: August 1, 2026
Blephamide is an ophthalmic corticosteroid-antibiotic combination containing prednisolone acetate 0.2% and sulfacetamide sodium 10%. Public evidence does not show an active interventional clinical-trial program, a current biosimilar pathway, or a meaningful composition-of-matter patent barrier. Its commercial outlook is therefore driven by prescription demand, generic substitution, manufacturing continuity, ophthalmology prescribing patterns, and product availability rather than clinical innovation or patent exclusivity.
What is Blephamide and what is it used for?
Blephamide is marketed for steroid-responsive inflammatory conditions of the eye when bacterial infection or a risk of bacterial infection exists. The product is available in ophthalmic suspension and ointment formulations in certain markets and is used for conditions involving the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye, subject to the product labeling.
| Product |
Active ingredients |
Route |
Principal use |
| Blephamide ophthalmic suspension |
Prednisolone acetate 0.2%; sulfacetamide sodium 10% |
Ophthalmic |
Steroid-responsive ocular inflammation with bacterial infection or risk |
| Blephamide ophthalmic ointment |
Prednisolone acetate 0.2%; sulfacetamide sodium 10% |
Ophthalmic |
Similar indication where an ointment dosage form is appropriate |
Prednisolone acetate is the anti-inflammatory corticosteroid. Sulfacetamide sodium is a sulfonamide antibacterial agent. The combination is intended for short-term treatment under ophthalmic supervision because topical corticosteroids can increase intraocular pressure, delay corneal healing, worsen undiagnosed infections, and mask infection progression.[1]
What is the FDA regulatory status of Blephamide?
Blephamide is an established prescription ophthalmic product rather than a newly developed drug. Its regulatory value comes from an approved combination of known active ingredients and dosage forms.
The FDA labeling identifies the product as an ophthalmic combination of prednisolone acetate and sulfacetamide sodium. The label carries the standard corticosteroid warnings concerning glaucoma, cataract formation, delayed healing, and exacerbation of ocular infection.[1]
FDA status and regulatory characteristics
| Regulatory issue |
Assessment |
| Product category |
Prescription ophthalmic drug |
| Active ingredients |
Prednisolone acetate and sulfacetamide sodium |
| FDA pathway |
Legacy approved product; current competition may proceed through abbreviated pathways where applicable |
| Biologic status |
Not a biologic |
| Biosimilar pathway |
Not applicable |
| Pediatric exclusivity |
No current public evidence of a new pediatric exclusivity period |
| Orphan-drug exclusivity |
No public evidence of orphan designation |
| New chemical entity exclusivity |
Not applicable to these established active ingredients |
| Clinical development status |
No identifiable active late-stage development program |
The primary regulatory risks are manufacturing quality, sterility, container-closure performance, labeling compliance, and supply continuity. Ophthalmic suspensions and ointments require controls that do not apply to ordinary oral solid products, including microbial quality, particle-size control, dose uniformity, preservative performance where applicable, and compatibility with the dispensing container.
Are there active clinical trials for Blephamide?
Public clinical-trial records do not indicate a current, sponsor-led clinical development program for Blephamide as a branded product. The product has an established clinical history, and its active ingredients have been studied extensively in ophthalmology, but that evidence is different from an active modern trial program for Blephamide.
ClinicalTrials.gov records may contain studies involving prednisolone, sulfacetamide, corticosteroid-antibiotic combinations, conjunctivitis, blepharitis, or postoperative ocular inflammation. Those studies should not be treated as Blephamide trials unless the record identifies the specific product, formulation, sponsor, and dosing regimen.[2]
Clinical-trial outlook
| Trial category |
Current relevance to Blephamide |
| New pivotal efficacy trials |
Low |
| Phase 1 or Phase 2 development |
No identifiable active program |
| Postmarketing safety study |
No prominent current program identified |
| Comparative generic study |
Possible for abbreviated approval, but individual records may not be publicly detailed |
| Studies of prednisolone acetate |
Relevant to the corticosteroid component but not necessarily to Blephamide |
| Studies of sulfacetamide sodium |
Relevant to the antibacterial component but not necessarily to Blephamide |
| Combination-product trials |
Limited public development activity |
The lack of a visible trial program limits the probability of a near-term label expansion. A future study could support a revised indication, a preservative-free version, a new delivery system, or a different pediatric use, but no such development program is publicly established.
What patents protect Blephamide?
Blephamide is unlikely to have meaningful remaining composition-of-matter patent protection. Prednisolone acetate and sulfacetamide sodium are established active ingredients, and any historical patent protection would be expected to have expired long before the current commercial period.
The relevant IP questions concern formulation, manufacturing, container systems, trademarks, and regulatory exclusivity rather than the active ingredients themselves.
Patent estate assessment
| IP category |
Commercial significance |
| Prednisolone acetate composition patent |
Historical protection would be expired |
| Sulfacetamide sodium composition patent |
Historical protection would be expired |
| Combination patent |
No widely recognized current blocking patent identified |
| Ophthalmic suspension formulation |
May have supported historical product differentiation; enforceability depends on claim scope and expiration |
| Ophthalmic ointment formulation |
Potential formulation claims, but no established current blocking estate |
| Manufacturing process |
May create operational know-how but is difficult to use as a broad market barrier without enforceable claims |
| Container-closure system |
May support product performance or regulatory differentiation |
| Trademark |
Brand protection can remain distinct from patent protection |
| Regulatory exclusivity |
No current exclusivity period expected to block established generic competition |
When does Blephamide lose exclusivity?
Blephamide’s meaningful patent and regulatory exclusivity has effectively expired. The product is exposed to generic and therapeutically substitutable competition. A trademark may continue to protect the Blephamide name, but trademark protection does not prevent competitors from marketing equivalent products under different names.
The absence of current exclusivity does not guarantee immediate generic entry. Ophthalmic products can face technical and regulatory barriers, including sterile manufacturing capacity, suspension uniformity, stability, preservative systems, and reliable ophthalmic packaging.
What is the Orange Book status of Blephamide?
The FDA Orange Book is the principal source for determining listed patents, therapeutic-equivalence evaluations, reference-listed-drug status, and approved multisource competition. Blephamide’s Orange Book relevance depends on the specific dosage form and current listing status of the reference product.
A product can have commercial exposure to generic substitution even when its patent section contains no active blocking patent. For legacy products, the key Orange Book questions are whether a product is listed as the reference drug, whether an approved abbreviated new drug application exists, and whether therapeutic-equivalence codes support pharmacy-level substitution under state law.[3]
| Orange Book issue |
Practical implication |
| Listed reference product |
Establishes the reference point for an ANDA |
| Listed patents |
Determines whether a Paragraph IV certification or other patent certification is required |
| Therapeutic-equivalence code |
Influences substitution and payer treatment |
| Dosage-form listing |
Suspension and ointment products may have separate competitive dynamics |
| Discontinued or inactive listing |
Can affect the ability of a product to support new abbreviated approvals |
Product-level Orange Book records should be reviewed by dosage form, strength, applicant, and current marketing status. The commercial conclusion remains clear: Blephamide does not appear to rely on an active patent wall comparable to a modern branded ophthalmic franchise.
Which companies are challenging Blephamide?
Competition is more likely to come from generic manufacturers and alternative ophthalmic products than from a named litigation campaign against a currently valuable patent estate.
Potential competitors include manufacturers of:
- Prednisolone acetate ophthalmic suspension
- Sulfacetamide ophthalmic products
- Prednisolone-antibiotic combination products
- Tobramycin-dexamethasone ophthalmic products
- Neomycin-polymyxin B-dexamethasone products
- Other corticosteroid-antibiotic ophthalmic formulations
These products are not automatically clinical substitutes. Their active ingredients, potency, antimicrobial coverage, dosing schedules, contraindications, and therapeutic-equivalence status differ.
Competitive set
| Competitor category |
Competitive effect |
| Generic prednisolone acetate |
Competes for the steroid component but does not duplicate antibacterial coverage |
| Generic sulfacetamide ophthalmic products |
Competes for antibacterial treatment but lacks corticosteroid activity |
| Corticosteroid-antibiotic combinations |
Provides the closest therapeutic substitution |
| Tobramycin-dexamethasone products |
Competes in postoperative and inflammatory ocular conditions |
| Neomycin-polymyxin B-steroid products |
Competes where broader antibacterial combinations are selected |
| Off-label or alternative regimens |
Can reduce demand in mild or uncertain infections |
What patent litigation affects Blephamide?
No major current patent litigation involving Blephamide is widely recognized as a material commercial event. The product’s age and lack of an apparent active blocking patent estate reduce the probability of high-value Paragraph IV litigation.
Potential disputes would more likely involve:
- ANDA approval or product-specific formulation issues
- Trade dress or trademark rights
- False advertising or substitution claims
- Manufacturing, sterility, or product-quality issues
- Contract manufacturing and supply agreements
- Regulatory interpretation involving dosage-form equivalence
Paragraph IV challenge risk
Paragraph IV litigation is generally associated with an ANDA applicant asserting that listed patents are invalid, unenforceable, or not infringed. For a legacy product with no material unexpired blocking patents, the commercial relevance of Paragraph IV activity is limited.
A generic applicant could still face regulatory or technical review issues even without patent litigation. Those issues may include demonstrating pharmaceutical equivalence, bioequivalence where applicable, formulation comparability, sterility, stability, and container performance.
How strong is the Blephamide patent estate?
The Blephamide patent estate is weak as a market-exclusion tool. Its principal defenses are likely brand recognition, physician familiarity, supply reliability, manufacturing know-how, and regulatory execution.
| Patent-strength factor |
Rating |
Rationale |
| Composition-of-matter protection |
Low |
Established active ingredients |
| Remaining regulatory exclusivity |
Low |
No current exclusivity period is apparent |
| Formulation protection |
Low to moderate |
Legacy formulation claims may exist but are unlikely to create a broad current barrier |
| Manufacturing protection |
Moderate operationally |
Sterile ophthalmic production is technically demanding |
| Trademark protection |
Moderate |
Brand identity remains protectable |
| Litigation leverage |
Low |
No apparent high-value blocking estate |
| Generic-entry resistance |
Low to moderate |
Technical barriers remain despite limited patent protection |
What market factors determine Blephamide revenue?
Blephamide revenue is likely concentrated in a narrow ophthalmic niche. Public product-level revenue disclosure is limited, particularly where the product is part of a larger ophthalmology portfolio. A precise independent revenue figure or long-range market forecast is therefore not established by public regulatory records.
The main revenue drivers are:
- Prescription volume for steroid-responsive ocular inflammation.
- Availability of lower-cost generic alternatives.
- Payer formulary placement and pharmacy substitution.
- Physician preference for a known combination product.
- Product shortages affecting competitors.
- Continuing demand for an ointment or suspension dosage form.
- Ophthalmology and optometry prescribing trends.
- Safety concerns associated with sulfonamide allergy, corticosteroid exposure, and antimicrobial stewardship.
The product may retain value in situations where clinicians prefer a combination formulation over prescribing separate steroid and antibacterial products. That advantage is limited by generic substitution and the availability of competing combinations.
What is the Blephamide market projection?
Blephamide is best classified as a mature, low-growth prescription ophthalmic product. The base-case projection is stable-to-declining branded demand, with periodic volume volatility caused by generic availability, shortages, price changes, and portfolio decisions.
| Projection period |
Expected market direction |
Primary drivers |
| Near term |
Stable to modest decline |
Generic substitution, mature prescribing base |
| Medium term |
Decline in branded share |
Price competition and alternative combinations |
| Longer term |
Niche persistence possible |
Brand familiarity, dosage-form demand, supply events |
Bull-case scenario
A favorable outcome would require one or more of the following:
- Competitor shortages
- Successful price or contracting strategy
- Continued physician preference for the branded product
- Reliable supply of both suspension and ointment forms
- Limited generic availability in specific channels
- Expanded distribution or stronger ophthalmology promotion
Base-case scenario
The most likely outcome is continued availability as a niche legacy product, with generic competition limiting price growth and reducing branded market share. Revenue would depend more on supply execution and channel access than on new clinical data.
Bear-case scenario
Downside would result from:
- Multiple therapeutically equivalent generic entrants
- Permanent discontinuation of a dosage form
- Manufacturing or sterility problems
- Payer exclusion
- Substitution by newer corticosteroid-antibiotic combinations
- Reduced use of sulfonamide-containing ophthalmic products
How does Blephamide compare with newer ophthalmic combinations?
Blephamide has the advantage of long clinical familiarity but lacks the commercial protections associated with newer products, proprietary delivery systems, or novel active ingredients.
| Factor |
Blephamide |
Newer branded ophthalmic combinations |
| Active ingredients |
Established steroid plus sulfonamide |
May use newer antibiotics or delivery systems |
| Patent position |
Generally weak or expired |
Potentially stronger |
| Clinical evidence |
Historical and established |
May include modern comparative or indication-specific data |
| Pricing power |
Limited |
Higher if exclusivity remains |
| Generic exposure |
High |
Depends on patent and exclusivity status |
| Differentiation |
Combination and brand familiarity |
Formulation, dosing, safety, or delivery technology |
| Commercial growth |
Low |
Can be higher during exclusivity period |
What manufacturing and IP barriers affect generic entry?
The principal barrier is technical execution rather than patent exclusion. Ophthalmic products must meet sterile manufacturing standards and maintain consistent performance throughout shelf life.
Key manufacturing risks include:
- Sterility assurance
- Particle-size distribution in suspension products
- Redispersibility after storage
- Uniform delivery from the container
- Preservative effectiveness
- Container-closure integrity
- Stability under shipping and temperature conditions
- Ointment homogeneity
- Cross-contamination control in sterile facilities
These requirements can delay or discourage entry, especially where the expected market is small and price competition is intense. They do not create the same durable exclusivity as a valid, enforceable patent.
Key Takeaways
- Blephamide contains prednisolone acetate 0.2% and sulfacetamide sodium 10%.
- It is an established prescription ophthalmic combination for steroid-responsive inflammation with bacterial infection or risk.
- No active, material clinical-trial program for the branded product is publicly evident.
- The product is not a biologic and has no biosimilar pathway.
- Meaningful composition-of-matter and regulatory exclusivity have expired.
- The current patent estate appears weak as a barrier to generic entry.
- Commercial competition comes from generic components and other steroid-antibiotic ophthalmic combinations.
- No major current patent litigation appears to materially affect the product.
- Revenue is likely niche and mature, with stable-to-declining branded demand.
- Manufacturing quality, sterile capacity, supply reliability, and payer access are more important than patent protection.
FAQs About Blephamide
Is Blephamide still available?
Blephamide availability depends on the specific dosage form, manufacturer, distributor, and market. Ophthalmic products can experience intermittent shortages or discontinuations even when demand persists.
Is Blephamide stronger than prednisolone acetate alone?
Blephamide adds sulfacetamide antibacterial activity to prednisolone acetate. It is not simply a stronger steroid product. The combination is selected when both inflammation and bacterial infection or infection risk are clinically relevant.
Can generic manufacturers substitute for Blephamide?
Substitution depends on the specific generic product, dosage form, therapeutic-equivalence determination, pharmacy law, and prescriber instructions. A generic prednisolone product alone is not automatically equivalent to the combination product.
Does Blephamide have a pediatric indication?
Use in children depends on the approved labeling, clinical circumstances, and ophthalmologist judgment. Corticosteroid ophthalmic products require careful monitoring in pediatric patients because of intraocular-pressure and infection risks.
Is Blephamide subject to biosimilar competition?
No. Blephamide is a conventional small-molecule ophthalmic drug, not a biologic. Any competition would arise through generic-drug pathways rather than biosimilar approval.
References
-
U.S. Food and Drug Administration. (n.d.). Blephamide ophthalmic suspension prescribing information. FDA labeling database.
-
U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov search results for Blephamide, prednisolone acetate, and sulfacetamide ophthalmic products. ClinicalTrials.gov.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
